GENI.L Stock - GENinCode plc
Unlock GoAI Insights for GENI.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.70M | $2.16M | $1.43M | $1.15M | $960,801 |
| Gross Profit | $1.43M | $1.02M | $632,000 | $593,000 | $523,016 |
| Gross Margin | 52.8% | 47.3% | 44.2% | 51.4% | 54.4% |
| Operating Income | $-5,134,000 | $-7,151,000 | $-5,899,000 | $-3,534,000 | $-1,050,004 |
| Net Income | $-4,434,000 | $-7,016,000 | $-5,559,000 | $-4,142,000 | $-1,166,000 |
| Net Margin | -164.2% | -324.8% | -388.7% | -358.9% | -121.4% |
| EPS | $-0.03 | $-0.07 | $-0.06 | $-0.08 | $-0.01 |
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
Visit WebsiteEarnings History & Surprises
GENI.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 30, 2025 | — | $-0.01 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.01 | — | — |
Q3 2024 | Sep 25, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 9, 2024 | $-0.03 | $-0.04 | -11.2% | ✗ MISS |
Q3 2023 | Sep 20, 2023 | — | $-0.04 | — | — |
Q2 2023 | May 31, 2023 | — | $-0.03 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.06 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.07 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-3.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-3.01 | — | — |
Latest News
Frequently Asked Questions about GENI.L
What is GENI.L's current stock price?
What is the analyst price target for GENI.L?
What sector is GENinCode plc in?
What is GENI.L's market cap?
Does GENI.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GENI.L for comparison